Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

172

Citations

20

References

2022

Year

Michael J. Soileau, Jason Aldred, Kumar Budur, Nahome Fisseha, Victor SC Fung, Anna Jeong, Thomas Kimber, Kevin J. Klos, Irene Litvan, Daniel I. O’Neill,

The Lancet Neurology

Advanced ParkinsonParkinson DiseaseNeurologyMedicineContinuous Subcutaneous Foslevodopa-foscarbidopaMovement Disorders

References

	Year	Citations

Page 1